This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Weichai Power Wants Hydrogen to Fuel Us – and Itself
Weichai Power announced that it would insist on developing hydrogen fuel, no matter how the social support for this might wax or wane. The technology is most appropriate for commercial vehicles – a convenient way for the firm to develop.
Oct 03, 2020 05:22 AM
Defining key tasks and accelerating the construction of new urbanization